Abstract
Background Asthma and diabetes are both diseases that affect a wide range of people worldwide. As a common treatment for diabetes, metformin has also been reported to be effective in improving asthma outcomes. We conducted a combined analysis to examine the efficacy of metformin in reducing asthma exacerbation in patients with concurrent asthma and diabetes. Methods We searched the PubMed, Embase, and CENTRAL databases for articles published prior to April 2020 to find observational studies of individuals with concurrent asthma and diabetes that compared the risk of asthma exacerbation between metformin users and nonusers. Two researchers separately screened the studies, extracted data, and evaluated the risk of bias. The primary outcome was the adjusted risk of asthma exacerbation. The secondary outcomes were the adjusted risk of asthma-related hospitalization and emergency room visits. Review Manager was used for data analysis and plotting. I2 and χ2 tests were used to estimate heterogeneity. A random effects or fixed effects model was used depending on the heterogeneity. Odds ratios were calculated for dichotomous variables. Results We included two studies with a total of 25252 patients. The pooled effect size showed that metformin was inversely associated with a risk of asthma exacerbation (OR = 0.65, 95% CI 0.28–1.48; χ2 = 5.42, P=0.02; I2 = 82%), asthma-related emergency department visits (OR = 0.81, 95% CI 0.74–0.89; χ2 = 0.36, P=0.55; I2 = 0%), and hospitalizations (OR = 0.43, 95% CI 0.14–1.29; χ2 = 4.01, P=0.05; I2 = 75%). Conclusion This meta-analysis suggested that metformin decreased the risk of asthma-related emergency room visits for patients with concurrent asthma and diabetes. Metformin reduced the risk of asthma-related hospitalization and exacerbation but was not statistically significant. More randomized trials involving larger samples should be considered, and the mechanisms of these effects need to be fully elucidated.
Highlights
Asthma, a chronic inflammatory disease of the small airway characterized by recurring wheezing, reversible airflow obstruction, cough, and other symptoms [1], affects more than 300 million people worldwide [2]. e WHO estimates that 235 million people currently suffer from asthma [3]
Two observational studies were included in the present meta-analysis, and the characteristics of the studies are shown in Table 1. e two trials were high-quality studies. e Newcastle-Ottawa Scale was used to evaluate the risk of bias for the observational studies (Table 2)
Metformin decreased the risk of asthma-related hospitalization, but 145 of records identified through database searching PubMed, n = 49 Embase, n = 88 CENTRAL, n = 8
Summary
A chronic inflammatory disease of the small airway characterized by recurring wheezing, reversible airflow obstruction, cough, and other symptoms [1], affects more than 300 million people worldwide [2]. e WHO estimates that 235 million people currently suffer from asthma [3]. As a common treatment for diabetes, metformin has been reported to be effective in improving asthma outcomes. We conducted a combined analysis to examine the efficacy of metformin in reducing asthma exacerbation in patients with concurrent asthma and diabetes. E secondary outcomes were the adjusted risk of asthma-related hospitalization and emergency room visits. E pooled effect size showed that metformin was inversely associated with a risk of asthma exacerbation (OR 0.65, 95% CI 0.28–1.48; χ2 5.42, P 0.02; I2 82%), asthma-related emergency department visits (OR 0.81, 95% CI 0.74–0.89; χ2 0.36, P 0.55; I2 0%), and hospitalizations (OR 0.43, 95% CI 0.14–1.29; χ2 4.01, P 0.05; I2 75%). Is meta-analysis suggested that metformin decreased the risk of asthma-related emergency room visits for patients with concurrent asthma and diabetes. More randomized trials involving larger samples should be considered, and the mechanisms of these effects need to be fully elucidated
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
